CSS
GTBP icon

Cubist Systematic Strategies’s GT Biopharma GTBP Stock Holding History

Cubist Systematic Strategies’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-349
Closed -$3.26K – 3570
2023
Q2 		$3.26K Buy
+349
New +$3.62K ﹤0.01% 3336
2021
Q4 		– Sell
-1,123
Closed -$227K – 3527
2021
Q3 		$227K Buy
+1,123
New +$338K ﹤0.01% 2514

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFS
Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's GTBP Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of GT Biopharma (GTBP) in Q3 2023, closing a stake of 349 shares — an estimated $3.26K sold.

Cubist Systematic Strategies first reported a position in GTBP in Q3 2021 and held it in 2 quarters. The position peaked at $227K in Q3 2021. 32 funds tracked by Wall St. Rank hold GTBP as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining GT Biopharma position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 349 GT Biopharma shares in Q3 2023, an estimated $3.26K.
  • Cubist Systematic Strategies first reported a position in GT Biopharma in Q3 2021 and held it in 2 quarters.
  • Cubist Systematic Strategies's GT Biopharma position peaked at $227K in Q3 2021.
  • 32 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.